Back to the Virtual Exhibit Hall

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class immunology, immuno-oncology and anti-addiction therapeutics. Omeros’ pipeline is led by its complement franchise of protein and orally available small-molecule drug candidates targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and MASP-3, the key activator of the alternative pathway.

Contact Email:



Steve Russo

Manager, Market Development, Northeast | Omeros Corporation|

201 Elliott Avenue West | Seattle, WA. 98119 |

E:| CP: (203) 675-3134 |


Disease State Education Site



PDF icon EIS_brochure.pdf

PDF icon HSCT_TMA_Clinical_Triad.pdf